Tag Archives: torcetrapib
Even the best and the brightest can stumble. Need proof? Just chew on the latest news from Pfizer (NYSE: PFE). Over the weekend, PFE announced it was halting development of the most promising drug in its pipeline, torcetrapib. However, I am hopeful but realistic that PFE can regain the offensive and grow its business again within a reasonable time frame.